StockNews.AI
SEER
StockNews.AI
7 hrs

Seer Highlights How Proteomics Complements Genomics to Advance Precision Medicine at American Society of Human Genetics (ASHG) 2025

1. Seer showcased its Proteograph Suite at ASHG 2025 meeting in Boston. 2. Proteomics is critical for understanding disease biology and precision medicine. 3. Independent studies highlight Proteograph's adoption in translational genomics. 4. Findings presented indicate novel biomarker discovery and enhanced clinical insights. 5. CEO emphasizes importance of Proteograph in driving biological function connections.

6m saved
Insight
Article

FAQ

Why Bullish?

Seer is gaining visibility and recognition at a prominent genetics conference, resembling past instances where such exposure led to positive stock performance for biotech firms, notably Illumina during genomics conferences.

How important is it?

The article highlights key advancements in Seer's technology and its applications, which can attract investors and researchers, directly influencing stock performance due to increased interest and credibility.

Why Short Term?

The upcoming conference and presentations are likely to boost investor sentiment and interest immediately, as seen in other biotech events that typically result in short-term stock price spikes.

Related Companies

ILMNBMRNNVTA
Scientific presentations reveal how Seer’s Proteograph Product Suite is a critical component of multi-omic translational studies and enables profiling of protein isoform-specific biomarkers October 10, 2025 07:00 ET  | Source: Seer, Inc. REDWOOD CITY, Calif., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced its participation at the upcoming American Society of Human Genetics (ASHG) 2025 Annual Meeting, taking place October 14-18 in Boston. As human genetics research increasingly moves from sequence to function, Seer’s presence at ASHG reflects how proteomics is becoming an essential complement to genomics in understanding disease biology and accelerating precision medicine. Seer will host a featured CoLab session and will be represented in multiple scientific presentations demonstrating how the Proteograph® Product Suite enables researchers to translate genomic data into biological and clinical insight. Seer CoLab Session Advancing Precision Medicine Through Multi-Omics: Clinical Insights from Xenotransplantation and FibrosisDate/Time: October 16, 2025 | 2:30-3:00 p.m. ETLocation: Theater 1, Exhibit Hall This featured session will highlight how multi-omic approaches powered by Seer’s Proteograph Product Suite are transforming translational genomics and clinical research. Brendan Keating, PhD, Associate Professor, NYU Langone Health, will present findings from gene-edited pig organ xenotransplants into humans, where integrated omics revealed immune and physiological dynamics critical for advancing compassionate use and first-in-human trials.Gloria Sheynkman, PhD, Assistant Professor, University of Virginia School of Medicine, will discuss how proteomic profiling identified isoform-specific biomarkers predicting survival differences in idiopathic pulmonary fibrosis, pointing to new avenues for targeted therapy in complex disease. Together, these talks show how proteomics and genomics converge to uncover novel biomarkers, deepen understanding of disease mechanisms, and advance clinical translation. Scientific Presentations Featuring Seer Technology In addition to the CoLab session, several independent research groups will present findings generated using Seer’s Proteograph platform, reflecting its growing adoption across global academic and clinical institutions. These studies explore how Seer’s proteomic data can clarify and enhance prior findings from affinity-based methods and integrate with genomic datasets for disease discovery. Triangulating orthogonal proteomic profiling methods to yield high-confidence protein targetsPresenter: Joshua Bis Date/Time: October 16, 2025 | 12:00-1:00 p.m. | Poster 4063TProteogenomic prioritization of human knock-out mutations provides novel insights into function and clinical impact of genes across the genome and clinical specialtiesPresenter: Claudia LangenbergDate/Time: October 16, 2025 | 2:30-4:30 p.m. | Poster Session 4105T | Proteogenomics “It’s remarkable to see how rapidly proteomics is rising in importance among genomics researchers, as reflected in the many exciting presentations at ASHG,” said Omid Farokhzad, Chair and CEO of Seer. “Proteins are the functional drivers of biology, and the proteome is extraordinarily complex. Empowering researchers to connect genetic variation to biological function through deep, unbiased proteomics at scale will help unlock the next phase of precision medicine. We’re thrilled to see so many researchers choosing Seer’s platform to help them make these connections and discoveries.” About Seer, Inc. Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with scale, speed, precision, and reproducibility previously unattainable by other proteomic methods. Seer’s Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer’s robust and scalable workflow consistently reveals biological insights that others do not. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information about Seer’s differentiated approach and ongoing leadership in proteomics, visit www.seer.bio. For more information, please visit booth #2586 or contact us at pr@seer.bio. Media Contact:Patrick Schmidtpr@seer.bio Investor Contact:Carrie Mendivilinvestor@seer.bio

Related News